KDA Group Says Medherize Platform Evaluation Shows "Measurable Benefits" in Breast Cancer Patient Care
KDA Group (KDA.V) on Thursday said an evaluation of its digital platform Medherize in breast-cancer patients care showed "measurable benefits" for patients and care teams.The evaluation was conducted by the Breast Disease Centre of CHU de Quebec - Universite Laval, on 243 patients with breast cancer on certain targeted oral therapies between September 2025 and March 2026.According to a statement, the platform adoption rate was 97% among eligible patients and treatment adherence of 93% surpassed the 70% to 90% generally reported in the literature for oral oncology treatments. More than four in five or 86% were satisfied with the clarity of information, KDA added.Care teams also reported an 80% decline in medical consultations and administrative interventions, along with a halving (52%) in the "required pharmacist full-time equivalent"."These results confirm what we set out to achieve in designing the Adherize+ platform with the Medherize module: to refocus teams' attention on clinically significant situations while strengthening patient autonomy. That an independent evaluation conducted in a hospital setting demonstrates this is an important validation for the future," said chief executive Jean-Marc Leveille.KDA shares last traded on June 15, closing at $0.075 on the TSX Venture Exchange.
